Background

The natural polyphenol resveratrol (RSV) is found in certain berries, grapes and plants [1] were it exerts anti-fungal and anti-oxidative effects [2]. In humans, RSV is also shown to possess anti-inflammatory and anti-oxidative properties [1]. The anti-inflammatory effect has been shown in both immune cells [3,4,

Results

Viability and differentiation of cells

48 h- and 21 days SFMC cultures were assessed under a microscope for viability after the incubation period. Fig. 1 shows images of untreated and RSV treated cultures. Viable cells were present in similar densities for both. No visible cell toxicity was detected in medium with dimethyl sulfoxide compared to medium alone. Furthermore, 21 days SFMC cultures showed presence of multinucleated cells, as shown previously [21]. Enzyme analysis on untreated 21 days SFMC cultures showed TRAP activity in 8 cultures. An additional file shows similar cell viability in 48 h and 21 days SFMC cultures that was untreated or treated with RSV, MTX and adalimumab; Additional file 1.

Fig. 1
figure 1

Cell culture viability assessed in microscope (× 10) of 48 h- and 21 days SFMC cultures after incubation period. No immediate cell loss after RSV treatment (25 μM) compared to untreated (UT) cultures. 21 days SFMC cultures showed forming of multinucleated cells

Full size image

Resveratrol significantly decreased MCP-1 concentration in 48 h SFMC cultures without differences comparing response in RA and SpA patients

The measured concentrations/activity of MCP-1, MMP3 and TRAP in culture supernatants are presented in Fig. 2. RSV significantly decreased the concentration of MCP-1 in 48 h SFMC cultures (Fig. 2a, p = 0.005), and showed no significant difference when comparing MCP-1 ratios in samples from patients with RA and SpA (Fig. 3, p = 0.815). RSV did not change MMP3 concentration in 48 h SFMC cultures or MCP-1 concentration and TRAP activity in 21 days SFMC cultures (Fig. 2b-d).

Fig. 2
figure 2

Concentrations of MCP-1 (a, n = 14 and b, n = 8), MMP3 (c, n = 9) and TRAP activity (d, n = 8) in untreated (UT) and resveratrol (RSV) treated cultures measured by ELISA and enzyme activity assay in their respective supernatants. UT is presented as a negative control to its in-patient corresponding RSV treated culture, * p < 0.05. RSV concentration was 25 μM

Full size image
Fig. 3
figure 3

Ratio of MCP-1 in resveratrol (RSV) treated cultures (n = 14) divided in groups of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). MCP-1 was measured by ELISA. RSV concentration was 25 μM

Full size image

Resveratrol’s effect may be influenced by the level of disease activity and the cellular subset in synovial fluid

The effect of RSV on MCP-1 concentration in 48 h SFMC cultures was assessed in the subgroup analyses as described in the methods section. In short, subgroup changes in MCP-1 concentrations were compared based on DAS28CRP and the lymphocyte/monocyte count in the SFMC cultures (Fig. 4).

Fig. 4
figure 4

Ratio of MCP-1 in resveratrol (RSV) treated cultures (n = 11) plotted against DAS28CRP (a), and the percentage of monocytes (b) and lymphocytes (c) in synovial fluid of the donor. d-f depicts group comparisons as median and interquartiles. *p < 0.05 vs. negative control. MCP-1 was measured by ELISA. RSV concentration was 25 μM

Full size image

In the subgroup analysis, RSV induced a significant MCP-1 decrease only in cultures from patients with DAS28CRP ≤ 3.2, p = 0.028, low monocytes count (≤ 27%, p = 0.019), and high lymphocyte count (> 63%, p = 0.002).

The median MCP-1 ratio was significantly decreased in patients with DAS28CRP ≤ 3.2 vs. > 3.2 (p = 0.022) and when lymphocyte count was > 63% compared with patients with ≤ 63% (p = 0.03).

In 48 h SFMC cultures similar visual tendency was present for MMP3 ratios but no statistical significant correlation. Thus, the effect of RSV was most potent in cultures from patients with low DAS28CRP and a high percentage of lymphocytes in the synovial fluid. However, the limited number of MMP3 results made subgroup analysis inappropriate.

The 21 days SFMC cultures showed no statistically significant correlation of MCP-1 or TRAP ratios, when plotted against DAS28CRP, monocyte count or lymphocyte count. Subgroup analysis was again inappropriate due to the small number of data.

Resveratrol, methotrexate and adalimumab show similar MCP-1 lowering effects in 48 h SFMC cultures, but not 21 days SFMC cultures

To assess effects of different treatments, MCP-1 ratios (treated/untreated) from 48 h and 21 days SFMC culture were calculated. These ratios from RSV, MTX, MTX + RSV, adalimumab and adalimumab+RSV treatment are presented in Fig. 5. The ratios were then compared to identify differences in treatment effects.

Fig. 5
figure 5

Ratios of MCP-1 (a, n = 14 and b, n = 8 (RSV and MTX + RSV) or n = 7 (MTX, ADA and ADA + RSV)) and MMP3 (c, n = 9) concentrations, and TRAP activity (d, n = 8) in supernatants from cultures with the noted substance or a combination of resveratrol (RSV), Ebetrex (MTX) and Adalimumab (ADA). Concentrations were: RSV; 25 μM, MTX; 0.5 μg/ml, Adalimumab; 5 μg/ml. MCP-1 and MMP3 were measured by ELISA and TRAP with an enzyme activity assay. Data is presented as a dot for each measurement; box and bars represent median and interquartile range. *p < 0.05 vs. negative control

Full size image

In the 48 h SFMC cultures, MCP-1 ratios were significantly decreased by all the above-mentioned treatment conditions compared to no treatment (Fig. 5a). MMP3 ratios were not decreased significantly by any treatment (Fig. 5c), though RSV treatment resulted in the largest decrease (MMP3 ratio median = 0.77). MTX and adalimumab treatment did not result in a significantly different response compared to RSV in 48 h SFMC cultures and no additive effect of RSV was detected when including all cultures in the comparative analysis.

In 21 days SFMC cultures, MTX, MTX + RSV and adalimumab+RSV decreased median MCP-1 ratios, but only MTX + RSV produced a significant decrease. This was both when compared to the negative control (p = 0.008) and RSV alone (p = 0.0025). Adalimumab treatment produced a significant decrease in TRAP activity with and without RSV compared to no treatment (p = 0.023 and p = 0.008, respectively). No other treatment affected TRAP activity.

Potential additive effects of RSV may be influenced by the level of disease activity and cellular subset in synovial fluid

In subgroup analysis of the 48 h SFMC cultures, MTX significantly decreased MCP-1 ratios in patients with high lymphocyte count (> 63%). RSV + MTX significantly lowered MCP-1 in patients with DAS28CRP ≤ 3.2, DAS28CRP > 3.2, low monocyte count (≤ 27%) and high lymphocyte count (> 63%); Fig. 6a-c.

Fig. 6
figure 6

MCP-1 ratios as median and interquartiles in cultures treated with ebetrex (MTX) alone or in combination with resveratrol (RSV). Group comparisons were based on a) Disease Activity Score 28 (DAS28CRP), b) the percentage of monocytes and c) the percentage of lymphocytes in synovial fluid of the donor. *p < 0.05 vs. negative control. MCP-1 was measured by ELISA. Concentrations were: RSV = 25 μM and MTX = 0.5 μg/ml

Full size image

Moreover, the addition of RSV to MTX treatment produced a significant lower MCP-1 ratio than MTX alone in the subgroup with DAS28CRP ≤ 3.2, p = 0.016, DASCRP > 3.2, p = 0.036, low monocyte count (≤ 27%, p = 0.04) and in cultures with high lymphocyte count (> 63%, p = 0.011).

Figure 7a-c presents subgroup MCP-1 ratio results (48 h SFMC cultures) for treatment with adalimumab alone or in combination with RSV. Both treatments produced significantly lower MCP-1 ratios in several subgroups (Fig. 7a-c) compared to no treatment. The greatest decrease in MCP-1 ratio was produced by adalimumab in combination with RSV in subgroups with DAS28CRP ≤ 3,2, low monocyte count (≤ 27%) and high lymphocyte count (> 63%).

Fig. 7
figure 7

MCP-1 ratios as median and interquartiles in cultures treated with adalimumab (ADA) alone or in combination with resveratrol (RSV). Group comparisons were based on a) Disease Activity Score 28 (DAS28CRP), b) the percentage of monocytes and c) the percentage of lymphocytes in synovial fluid of the donor. *p < 0.05 vs. negative control. MCP-1 was measured by ELISA. Concentrations were: RSV = 25 μM and ADA = 5 μg/ml

Full size image

None of these ratios were, however, significantly different compared with adalimumab treatment alone.

Subgroup analysis was not carried out for MMP3 ratios in 48 h SFMC cultures and for MCP-1 and TRAP ratios from 21 days SMFC cultures due to the smaller number of cell cultures.

Discussion

A combination of two in vitro arthritis models was used to investigate the effects of RSV. RSV inhibited MCP-1 production in the 48 h inflammation model to a similar extent as MTX and adalimumab. This well-known anti-inflammatory property of RSV in vitro is in accord with previous reports [29, 34, 35]. Our results are to the author’s knowledge, however, the first to suggest that RSV’s anti-inflammatory effect may be influenced by the level of disease activity in patients with arthritis and composition of immune cells present in the cell cultures. Thus, RSV seemed to exert the greatest relative inhibition of MCP-1 in cultures from patients with low disease activity i.e. a DAS28CRP ≤ 3.2 or a synovial fluid infiltration dominated by lymphocytes.

RSV also resulted in a decrease of MMP3 ratio medians in 48 h SFMC cultures. However, this change was not significant as otherwise reported previously in fibroblast-like synoviocyte cultures from RA patients [8, 9]. Several parameters may offer an explanation to this. 1) The cellular composition of our models, i.e. SFMC may differ significantly from a fibroblast-like synoviocyte mono culture. 2) The mentioned studies only showed significant inhibition when cultures were additionally stimulated with TNF-α [8] or IL-1β [9], whereas our cultures received no additional stimulation in vitro. 3) The concentration of RSV may influence the effective inhibition of MMP3; Glehr et al. [9] used 100 μM versus our 25 μM, and Tian et al. [8] reported significant inhibition at 12.5, 25 and 50 μM. Despite differences, the two previous studies together with our data suggest an inhibitory effect of RSV on MMP3 production, and thereby a possible cartilage protective effect in relation to inflammatory arthritis.

RSV had no measurable effect on TRAP activity. This result is somewhat in conflict with previous reports were RSV is shown to diminish TRAP production in canine osteoclasts [36], and inhibit canine and murine osteoclastogenesis through various mechanisms [36, 37]. In contrast, our in vitro model received no additional stimulation, which may have limited our models’ ability to detect subtle changes in TRAP activity.

Osteoclasts are, however, not the only cell line of interest when evaluating RSV effects on arthritis. RSV has also been shown to attenuate pro-inflammatory processes in chondrocytes [30] and stimulates osteoblast differentiation [38]. Results that may give explanation for chondro-protective effects seen in osteoarthritic rabbits treated with intraarticular injections of RSV [39, 40].

Subgroup analysis of 48 h SFMC cultures showed RSV anti-inflammatory effect was most pronounced in cultures from patients with low disease activity and in patients with a synovial fluid dominated by lymphocytes. Our study was not designed to explain these differences. We therefore suggest further studies that investigate whether greater levels of systemic inflammation induce a different array of inflammatory pathways in these SFMCs, and whether pathways are affected differently by RSV at different levels of disease activity/inflammatory burden. It would also be interesting to see detailed investigations of the cellular subset, i.e. whether different lymphocyte subtypes are affected differently by RSV.

RSV has, to the author’s knowledge not been tested against or together with MTX or adalimumab in vitro or in vivo before. It is of great interest that the addition of RSV to MTX treatment showed significant additive effect especially in subgroups with low disease activity, or when the synovial fluid was dominated by lymphocytes. The effect in patients with DAS28CRP ≤ 3.2, is interesting because patients with low disease activity can still experience pain and discomfort. This encourages in vivo studies of the addition of RSV to MTX in patients with low disease activity. It should be mentioned that we did not have information about DAS28CRP in 4 patients which explains the differences in Fig. 5 (n = 14) and Fig. 6 (n = 10).

In addition to this, a previous study has reported that RSV protects against MTX induced oxidative stress in the small intestines of rats [41]. An interesting protective effect, since gastro-intestinal side effects from MTX are reported as a major reason for treatment discontinuation in RA patients [42]. Results from adalimumab treatment in the 48 h SFMC model, showed no significant additive effect of RSV, but did show same tendencies as with MTX.

Despite RSVs lipophilic nature and quick absorption from the small intestines, only relatively low amounts are found in the bloodstream after oral ingestion [43]. Studies explain this by a high rate of hepatic metabolism, which conjugates RSV with sulfates and glucuronides [1, 43]. Thus, a big challenge when discussing RSV as a possible drug candidate is drug delivery. Possible solutions could be a specific inhibition of the hepatic RSV metabolism or a delivery matrix that allows passage through the liver without major metabolism. Another possible delivery method is intraarticular injection of RSV. Animal studies have so far shown that intraarticular injected RSV reduce synovial hyperplasia and inflammation in an induced arthritis model [44], and attenuate if not prevent osteoarthritic progress in mice [45] and rabbits [39, 40].

As with all in vitro studies, the models used here have the fundamental limitation of only being a proxy to the in vivo situation, it seeks to investigate. This issue was addressed here by abstaining from additional stimulation of cultures, which in return may have diminished the study’s ability to detect subtle effects of RSV. The fact that this study in general have been limited to show trending effects of RSV and only few significant changes, may also be influenced by the relative small study population and unfortunate missing data from some cultures.

This study included a very heterogenous patient population with both RA and SpA patients on different disease modifying anti rheumatic drugs. RA and SpA both affect the synovial joints but also show very different clinical and immunological features. RSV treatment effect was not different when comparing SpA and RA in this study. Treatment with anti-TNFα or other disease modifying anti rheumatic drugs may affect immune cells even after isolation and thereby skew results from cultures. The potential influence of different treatments could not be studied due to the low sample size.

The study does, however, also possess strengths in its design and execution. First and foremost, the study combines both synovial fluid cells and osteoclasts involved in the osteoimmunological processes of inflammatory arthritis. The combination of models together with the different treatment conditions could allow interesting arguments across the pathological spectrum of inflammatory arthritis. The design furthermore permits the discovery of possible interactions between RSV, MTX and adalimumab, and enables it to suggest questions for future studies regarding RSVs effect at different levels of disease activity, inflammatory burden and on various cellular subsets.

Conclusion

To conclude, this study confirms RSV as an anti-inflammatory agent in our ex vivo model of immune mediated inflammatory arthritis. An effect which our data suggest can work synergistic with MTX; especially in cases of low disease activity making RSV a possible supplemental treatment. As a result, we suggest future investigations into interactions and potential additive effects of RSV in MTX treatment of patients with immune mediated inflammatory arthritis.